Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 16/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5491579 | 0.95 | TLR8 (0.44) | TLR8 | |
| SCHEMBL356920 | 0.88 | BACE1 (0.39) | TLR8 | |
| SCHEMBL7607407 | 0.85 | MPO (0.40) | TLR8 | |
| SCHEMBL7599129 | 0.83 | PNP (0.39) | — | |
| SCHEMBL7602254 | 0.83 | MPO (0.40) | TLR8 | |
| SCHEMBL7597747 | 0.83 | MPO (0.38) | TLR8 | |
| SCHEMBL20165 | 0.82 | DHFR (0.33) | — | |
| SCHEMBL11131695 | 0.81 | GPR84 (0.37) | TLR8GPR84 | |
| SCHEMBL7607707 | 0.78 | F13A1 (0.41) | TLR8 | |
| SCHEMBL542389 | 0.77 | PNP (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 581 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150211004-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-30 | — | — | US | claimed |
| EP-2838541-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | Agency For Science, Technology And Research (SG) | 2015-02-25 | — | — | EP | claimed |
| WO-2013158046-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-24 | — | — | WO | claimed |
| CN-122029282-A | Novel aptamers to EphA2 (hepaplatin receptor 2 a) | 阿普塔德尔治疗公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12606814-B2 | Oligonucleotide probes and uses thereof | CARIS SCIENCE, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260078383-A1 | RNA NANOSTRUCTURES AND METHODS OF MAKING AND USING RNA NANOSTRUCTURES | UNIV ARIZONA STATE (US) | 2026-03-19 | — | — | US | disclosed |
| US-12577627-B2 | Selective detection of different dengue virus RNA serotypes using tandem toehold-mediated displacement reactions | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONE STATE UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260041702-A1 | AGENTS THAT INHIBIT CCN LIGAND-INDUCED SIGNALLING FOR TREATING DISEASE | TRIBUNE THERAPEUTICS AB (SE) | 2026-02-12 | — | — | US | disclosed |
| EP-4683716-A1 | DNA NANODEVICES FOR SPECIFIC AND EFFICIENT DELIVERY OF FUNCTIONAL PAYLOADS TO THE CYTOPLASM AND METHODS OF THEIR USE | Arizona Board of Regents on behalf of Arizona State University (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4680212-A1 | ADAR1 INHIBITORS FOR TREATING CANCER | Institute of Cancer Research Royal Cancer Hospital (GB) | 2026-01-21 | — | — | EP | disclosed |
| US-20260014278-A1 | HYBRID PEPTIDE DENDRIMER SYSTEMS AND EXTRAHEPATIC DELIVERY | NUNTIUS THERAPEUTICS LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| US-5767264-A | ANTISENSE OLIGONUCLEOTIDES | MTA ZOZPONTI KEMIAI KUTATO INTEZET (HU) | 1998-06-16 | — | — | US | disclosed |
| US-5756291-A | IDENTIFYING OLIGOMER SEQUENCES; QUALITATIVE ANALYSIS; ANALYSIS OF THROMBIN BY COMPLEXING | GILEAD SCIENCES, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0681586-B1 | OLIGODEOXYNUCLEOTIDES CONTAINING 5-ALKYL-, 5-(1-ALKENYL)- AND 5-(1-ALKYNYL)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | MTA KOESPONTI KEMIAI KUTATO IN (HU) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996008559-A1 | GLYCOSAMINOGLYCAN-DEGRADING ENZYME INHIBITION AND RESULTANT DISEASE THERAPIES | CARDIAC CRC NOMINEES PTY. LTD. (AU) | 1996-03-21 | — | — | WO | disclosed |
| EP-0681586-A1 | OLIGODEOXYNUCLEOTIDES CONTAINING 5-ALKYL-, 5-(1-ALKENYL)- AND 5-(1-ALKYNYL)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | MTA Kösponti Kémiai Kutato Intézet (HU) | 1995-11-15 | — | — | EP | disclosed |
| WO-1994017094-A1 | OLIGODEOXYNUCLEOTIDES CONTAINING 5-ALKYL-, 5-(1-ALKENYL)- AND 5-(1-ALKYNYL)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | MTA KÖSPONTI KÉMIAI KUTATÓ INTÉZET (HU) | 1994-08-04 | — | — | WO | disclosed |
| EP-0572529-A1 | APTAMER SPECIFIC FOR BIOMOLECULES AND METHOD OF MAKING | GILEAD SCIENCES, INC. (US) | 1993-12-08 | — | — | EP | disclosed |
| WO-1992014842-A1 | APTAMERS SPECIFIC FOR THROMBIN AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
| WO-1992014843-A1 | APTAMER SPECIFIC FOR BIOMOLECULES AND METHOD OF MAKING | GILEAD SCIENCES, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577627-B2 | Selective detection of different dengue virus RNA serotypes using tandem toehold-mediated displacement reactions | DDX41, DDX5, DDX6 | TLR8 71/4885GPR84 4627/4885PI4KA 2275/4885 |
| US-12606814-B2 | Oligonucleotide probes and uses thereof | CD63, FLT4, NCL | TLR8 424/4885GPR84 3824/4885PI4KA 2790/4885 |
| US-20260041702-A1 | AGENTS THAT INHIBIT CCN LIGAND-INDUCED SIGNALLING FOR TREATING DISEASE | PKD2, CCNK, PKD1 | TLR8 634/4885GPR84 792/4885PI4KA 152/4885 |
| US-20260078383-A1 | RNA NANOSTRUCTURES AND METHODS OF MAKING AND USING RNA NANOSTRUCTURES | PDCD1, TIA1, NSUN2 | TLR8 473/4885GPR84 4027/4885PI4KA 4521/4885 |
| US-20260014278-A1 | HYBRID PEPTIDE DENDRIMER SYSTEMS AND EXTRAHEPATIC DELIVERY | CD47, CD2BP2, CD40LG | TLR8 1557/4885GPR84 1833/4885PI4KA 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.